Prevalence and possible role of non-H. pylori Helicobacter species in gastric conditions and cancers
Official title: The Prevalence and the Pathophysiological Role of Non-Helicobacter Pylori Helicobacter Spp. in Well-defined Gastric Diseases and (Pre-) Malignancies
Run by Universiteit Antwerpen · NCT07770126 · Data updated 2026-11-12
Researchers will test stomach tissue from people with functional dyspeasia, various gastritis conditions, gastric cancer, and bariatric patients to see if non-H. pylori Helicobacter species are present.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Universiteit Antwerpen Academic / other |
| Locations | 3 sites (Edegem and 2 other locations) |
| Status | Recruiting |
| Started | February 24, 2025 |
| Main results expected | March 2028 |
| Study ends | March 2028 |
| Registry record updated | August 18, 2026 |
| Trial ID | NCT07770126 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults undergoing endoscopy or gastric surgery for the listed conditions who have no history of H. pylori infection by serology, biopsy, breath test, or stool antigen.
✕Probably not a fit
Patients with prior H. pylori infection or those not undergoing biopsy/surgical specimens may not benefit from the findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects biopsy specimens from patients with functional dyspepsia, chronic gastritis, non-H. pylori atrophic gastritis with intestinal metaplasia or dysplasia, and gastric cancer, plus bariatric patients as controls. It aims to determine how often non-H. pylori Helicobacter species appear in these conditions. The analysis will use routinely obtained biopsy material to identify and characterize the bacteria's presence. The study is prospective and multicenter, leveraging specimens from multiple collaborating institutions. No interventions are described beyond specimen analysis.
Why it matters
Potential benefit: If non-H. pylori Helicobacter species are common, it could guide future diagnostics and targeted research for gastric diseases.
How similar studies have gone: Previous studies have investigated non-H. pylori Helicobacter species in gastric disease with varying prevalence, making this study's focused, prospective design informative.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * part of the study population Exclusion Criteria: * Patients with a history of H. pylori infection diagnosed by serology, on gastric biopsy, by breath test or on antigen test in stool samples. * Pregnancy. * Underage patients (\< 18 years).
Where it's running
-
Uza
Edegem, Belgium Recruiting -
AZ Maria Middelares
Ghent, Belgium Recruiting -
AZ Groeninge
Kortrijk, Belgium Recruiting
Study contacts
- Study coordinator: Jona Verstraelen, Master
- Email: Jona.Verstraelen@uantwerpen.be
- Phone: +32 32 65 14 28
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Observational study on gastric precancerous conditions
This study looks at people who are at higher risk for stomach cancer to see how conditions like atrophic gastritis and intestinal metaplasia develop over time.
-
Low-FODMAP Diet vs Standard Dietary Advice for Functional Dyspepsia
This study tests whether a low-FODMAP diet helps adults with functional dyspepsia compared with standard dietary advice.
-
Keverprazan-Minocycline Dual Therapy vs Bismuth Quadruple Therapy for H. pylori Eradication
This trial tests whether a keverprazan-minocycline dual therapy can eradicate Helicobacter pylori as well as or better than a bismuth-based quadruple therapy in adults who haven’t had eradication treatment before.
-
TEAS after gastrectomy to aid recovery after laparoscopic stomach cancer surgery
A randomized trial tests whether transcutaneous electrical acupoint stimulation (TEAS) after laparoscopic gastrectomy helps people recover faster and with less pain compared with a sham treatment.
-
Anti-PD-1 with chemotherapy and intraperitoneal nab-paclitaxel for untreated advanced gastric cancer with ascites
This study tests whether adding anti-PD-1 therapy to standard chemotherapy plus intraperitoneal nab-paclitaxel can help patients with untreated advanced gastric cancer and malignant ascites.
-
Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer
Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.